Sara De Martin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/669189/publications.pdf

Version: 2024-02-01

64 papers 1,604 citations

304743

22

h-index

330143 37 g-index

66 all docs

66
docs citations

66 times ranked 2001 citing authors

#	Article	IF	CITATIONS
1	REL-1017 (Esmethadone) as Adjunctive Treatment in Patients With Major Depressive Disorder: A Phase 2a Randomized Double-Blind Trial. American Journal of Psychiatry, 2022, 179, 122-131.	7.2	44
2	The Nuclear Receptor PXR in Chronic Liver Disease. Cells, 2022, 11, 61.	4.1	16
3	The Metabolic Activation of Sofosbuvir Is Impaired in an Experimental Model of NAFLD. Biology, 2022, 11, 693.	2.8	1
4	COVID-19 and Autoimmune Liver Diseases. Journal of Clinical Medicine, 2022, 11, 2681.	2.4	13
5	The N-Methyl-D-Aspartate Receptor Blocker REL-1017 (Esmethadone) Reduces Calcium Influx Induced by Glutamate, Quinolinic Acid, and Gentamicin. Pharmaceuticals, 2022, 15, 882.	3.8	6
6	Glabrescione B delivery by self-assembling micelles efficiently inhibits tumor growth in preclinical models of Hedgehog-dependent medulloblastoma. Cancer Letters, 2021, 499, 220-231.	7.2	22
7	Refill liquids for electronic cigarettes display peculiar toxicity on human endothelial cells. Toxicology Reports, 2021, 8, 456-462.	3.3	2
8	REL-1017 (Esmethadone) Increases Circulating BDNF Levels in Healthy Subjects of a Phase 1 Clinical Study. Frontiers in Pharmacology, 2021, 12, 671859.	3.5	17
9	Treatment of primary sclerosing cholangitis. Digestive and Liver Disease, 2021, 53, 1531-1538.	0.9	16
10	Cholangiocyte senescence in primary sclerosing cholangitis is associated with disease severity and prognosis. JHEP Reports, 2021, 3, 100286.	4.9	19
11	Folic Acid-Targeted Paclitaxel-Polymer Conjugates Exert Selective Cytotoxicity and Modulate Invasiveness of Colon Cancer Cells. Pharmaceutics, 2021, 13, 929.	4.5	12
12	The Role of Oxidative Stress in NAFLD–NASH–HCC Transition—Focus on NADPH Oxidases. Biomedicines, 2021, 9, 687.	3.2	46
13	The Extra Virgin Olive Oil Polyphenol Oleocanthal Exerts Antifibrotic Effects in the Liver. Frontiers in Nutrition, 2021, 8, 715183.	3.7	23
14	Tyrosine kinase inhibitor prodrug-loaded liposomes for controlled release at tumor microenvironment. Journal of Controlled Release, 2021, 340, 318-330.	9.9	8
15	In Vitro and in Vivo Behavior of Liposomes Decorated with PEGs with Different Chemical Features. Molecular Pharmaceutics, 2020, 17, 472-487.	4.6	18
16	PCSK9 Levels Are Raised in Chronic HCV Patients with Hepatocellular Carcinoma. Journal of Clinical Medicine, 2020, 9, 3134.	2.4	19
17	Impact of bariatric surgery-induced weight loss on circulating PCSK9 levels in obese patients. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 2372-2378.	2.6	5
18	Cuban Brown Propolis Interferes in the Crosstalk between Colorectal Cancer Cells and M2 Macrophages. Nutrients, 2020, 12, 2040.	4.1	9

#	Article	IF	CITATIONS
19	Depression and Cognitive Impairmentâ€"Extrahepatic Manifestations of NAFLD and NASH. Biomedicines, 2020, 8, 229.	3.2	60
20	Brown Seaweeds for the Management of Metabolic Syndrome and Associated Diseases. Molecules, 2020, 25, 4182.	3.8	34
21	The Cuban Propolis Component Nemorosone Inhibits Proliferation and Metastatic Properties of Human Colorectal Cancer Cells. International Journal of Molecular Sciences, 2020, 21, 1827.	4.1	22
22	Perception of illness in Italian patients with Primary Biliary Cholangitis referred to tertiary care units. Digestive and Liver Disease, 2020, 52, e6.	0.9	0
23	Role of cellular senescence in the natural history of primary sclerosing cholangitis. Digestive and Liver Disease, 2020, 52, e5-e6.	0.9	0
24	Fucus vesiculosus and Ascophyllum nodosum Ameliorate Liver Function by Reducing Diet-Induced Steatosis in Rats. Marine Drugs, 2020, 18, 62.	4.6	19
25	Gut microbial profiling as a therapeutic and diagnostic target for managing primary biliary cholangitis Expert Opinion on Orphan Drugs, 2020, 8, 507-514.	0.8	3
26	Western Diet-Induced Metabolic Alterations Affect Circulating Markers of Liver Function before the Development of Steatosis. Nutrients, 2019, 11, 1602.	4.1	29
27	FRI-082-Super stealth immunoliposomes as a strategy to overcome liposome-induced liver toxicity. Journal of Hepatology, 2019, 70, e420-e421.	3.7	0
28	Flavonoids Regulate Lipid Droplets Biogenesis in <i>Drosophila melanogaster</i> . Natural Product Communications, 2019, 14, 1934578X1985243.	0.5	9
29	Nemorosone inhibits the proliferation and migration of hepatocellular carcinoma cells. Life Sciences, 2019, 235, 116817.	4.3	19
30	Dopamine–mediated immunomodulation affects choroid plexus function. Brain, Behavior, and Immunity, 2019, 81, 138-150.	4.1	17
31	Live applications of norbormide-based fluorescent probes in Drosophila melanogaster. PLoS ONE, 2019, 14, e0211169.	2.5	8
32	The administration of a high-fat diet alters bile acid composition and hepatic drug metabolism in rats. Digestive and Liver Disease, 2019, 51, e22.	0.9	0
33	Extrahepatic autoimmunity in autoimmune liver disease. European Journal of Internal Medicine, 2019, 59, 1-7.	2.2	27
34	Targeting RORs nuclear receptors by novel synthetic steroidal inverse agonists for autoimmune disorders. Bioorganic and Medicinal Chemistry, 2018, 26, 1686-1704.	3.0	9
35	The inhibitory effect of ADM on hepatic NF-κB activation in 2D and 3D hepatic cell cultures. Digestive and Liver Disease, 2018, 50, 24.	0.9	0
36	The Brown Algae Fucus vesiculosus and Ascophyllum nodosum Reduce Metabolic Syndrome Risk Factors: A Clinical Study. Natural Product Communications, 2018, 13, 1934578X1801301.	0.5	11

#	Article	IF	CITATIONS
37	Dexamethasone counteracts hepatic inflammation and oxidative stress in cholestatic rats via CAR activation. PLoS ONE, 2018, 13, e0204336.	2.5	43
38	The ecto-enzymes CD73 and adenosine deaminase modulate 5′-AMP-derived adenosine in myofibroblasts of the rat small intestine. Purinergic Signalling, 2018, 14, 409-421.	2.2	11
39	Etiopathogenesis of autoimmune hepatitis. Journal of Autoimmunity, 2018, 95, 133-143.	6.5	105
40	Emerging players in liver fibrosis regression in a chronic murine model of hepatic injury. Digestive and Liver Disease, 2017, 49, e64.	0.9	0
41	Antibioticâ€induced dysbiosis of the microbiota impairs gut neuromuscular function in juvenile mice. British Journal of Pharmacology, 2017, 174, 3623-3639.	5.4	82
42	The Phytocomplex from Fucus vesiculosus and Ascophyllum nodosum Controls Postprandial Plasma Glucose Levels: An In Vitro and In Vivo Study in a Mouse Model of NASH. Marine Drugs, 2017, 15, 41.	4.6	46
43	Pregnane X receptor and constitutive androstane receptor modulate differently CYP3A-mediated metabolism in early- and late-stage cholestasis. World Journal of Gastroenterology, 2017, 23, 7519-7530.	3.3	22
44	An NBD Derivative of the Selective Rat Toxicant Norbormide as a New Probe for Living Cell Imaging. Frontiers in Pharmacology, 2016, 7, 315.	3 . 5	19
45	An intracellular adrenomedullin system reduces IL-6 release via a NF-kB-mediated, cAMP-independent transcriptional mechanism in rat thymic epithelial cells. Cytokine, 2016, 88, 136-143.	3.2	13
46	The balance between fibrosis and regeneration in chronic liver injury: The role of gender. Digestive and Liver Disease, 2016, 48, e26.	0.9	0
47	Pharmacokinetic drug interactions in liver disease: An update. World Journal of Gastroenterology, 2016, 22, 1260.	3.3	62
48	The activation of NF-kB, Pregnane X Receptor, and Constitutive Androstane Receptor is modulated by the degree of cholestasis. Digestive and Liver Disease, 2015, 47, e42.	0.9	0
49	NAD+-dependent SIRT1 deactivation has a key role on ischemia–reperfusion-induced apoptosis. Vascular Pharmacology, 2015, 70, 35-44.	2.1	48
50	Expression and Distribution of the Adrenomedullin System in Newborn Human Thymus. PLoS ONE, 2014, 9, e97592.	2.5	10
51	Differential Effect of Liver Cirrhosis on the Pregnane X Receptor–Mediated Induction of CYP3A1 and 3A2 in the Rat. Drug Metabolism and Disposition, 2014, 42, 1617-1626.	3.3	20
52	Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes. PLoS ONE, 2013, 8, e61983.	2.5	14
53	Differential Inducing Effect of Benzo[a]pyrene on Gene Expression and Enzyme Activity of Cytochromes P450 1A1 and 1A2 in Sprague-Dawley and Wistar Rats. Drug Metabolism and Pharmacokinetics, 2012, 27, 640-652.	2.2	22
54	Fluvoxamine pharmacokinetics in healthy elderly subjects and elderly patients with chronic heart failure. British Journal of Clinical Pharmacology, 2010, 69, 279-286.	2.4	22

#	Article	IF	CITATION
55	The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. Expert Opinion on Drug Metabolism and Toxicology, 2010, 6, 1215-1230.	3.3	11
56	Irreversible CYP3A Inhibition Accompanied by Plasma Protein–Binding Displacement: A Comparative Analysis in Subjects With Normal and Impaired Liver Function. Clinical Pharmacology and Therapeutics, 2009, 85, 319-326.	4.7	29
57	In vitro hepatic conversion of the anticancer agent nemorubicin to its active metabolite PNU-159682 in mice, rats and dogs: A comparison with human liver microsomes. Biochemical Pharmacology, 2008, 76, 784-795.	4.4	20
58	Enzyme Inhibition and Induction in Liver Disease. Current Clinical Pharmacology, 2008, 3, 56-69.	0.6	18
59	Co-administration of sirolimus alters tacrolimus pharmacokinetics in a dose-dependent manner in adult renal transplant recipients. Pharmacological Research, 2006, 54, 181-185.	7.1	27
60	Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2–mediated theophylline metabolism by fluvoxamine. Clinical Pharmacology and Therapeutics, 2006, 79, 489-499.	4.7	30
61	Differential effect of chronic renal failure on the pharmacokinetics of lidocaine in patients receiving and not receiving hemodialysis. Clinical Pharmacology and Therapeutics, 2006, 80, 597-606.	4.7	66
62	Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clinical Pharmacology and Therapeutics, 2004, 75, 80-88.	4.7	95
63	Effect of the CYP3A4 inhibitor erythromycin on the pharmacokinetics of lignocaine and its pharmacologically active metabolites in subjects with normal and impaired liver function. British Journal of Clinical Pharmacology, 2003, 55, 86-93.	2.4	46
64	Diagnostic Value of Plasma Cystatin C as a Glomerular Filtration Marker in Decompensated Liver Cirrhosis. Clinical Chemistry, 2002, 48, 850-858.	3.2	139